BridgeMD
New treatment option for Solid Tumors
Official title A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
ClinicalTrials.gov ID: NCT07123103
What this study is testing
What is XB371?
XB371 is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for solid tumors.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The primary purpose of the study is to characterize the safety and tolerability of XB371. The dose-escalation cohorts and Part B of the expansion cohorts are non-randomized.
- Phase 1: an early, usually small safety study
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
- Minimum life expectancy of ≥ 12 weeks.
- Recurrent locally advanced or metastatic solid tumors.
- Adequate end organ and bone marrow function. Key
You likely can't join if
- Primary brain tumors or known active brain metastases, leptomeningeal, or cranial epidural disease.
- History of interstitial lung disease (ILD) of any grade or history of organizing pneumonia.
- Has acute ocular infection, acute or chronic ulcerative/cicatricial condition of conjunctiva or cornea.
- Known history of immunodeficiency virus (HIV) unless specific criteria are met.
- Active infection with hepatitis C virus (HCV) defined as positive for HCV antibody.
- Major surgery within 4 weeks before the first dose of study treatment.
See the full eligibility criteria
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
- Minimum life expectancy of ≥ 12 weeks.
- Recurrent locally advanced or metastatic solid tumors.
- Adequate end organ and bone marrow function. Key
- Primary brain tumors or known active brain metastases, leptomeningeal, or cranial epidural disease.
- History of interstitial lung disease (ILD) of any grade or history of organizing pneumonia.
- Has acute ocular infection, acute or chronic ulcerative/cicatricial condition of conjunctiva or cornea.
- Known history of immunodeficiency virus (HIV) unless specific criteria are met.
- Active infection with hepatitis C virus (HCV) defined as positive for HCV antibody.
- Major surgery within 4 weeks before the first dose of study treatment.
- Received radiation therapy within 2 weeks before the first dose of study treatment.
- Received prior systemic anticancer therapy including investigational agents within 4 weeks before the first dose of study treatment. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
The study team makes the final eligibility decision.
Where it's taking place
- Rogers, Arkansas, United States
- Los Angeles, California, United States
- Washington D.C., District of Columbia, United States
- Orlando, Florida, United States
- Grand Rapids, Michigan, United States
- New Brunswick, New Jersey, United States
- Huntersville, North Carolina, United States
- Houston, Texas, United States
- San Antonio, Texas, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Rogers, Arkansas, United States; Los Angeles, California, United States; Washington D.C., District of Columbia, United States; Orlando, Florida, United States; Grand Rapids, Michigan, United States; New Brunswick, New Jersey, United States and 3 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.